Top Markets
#1 NKN NKN +163.44%
#2 Bluwhale Bluwhale +34.86%
#3 Codatta Codatta +29.93%
#4 SAFEcoin SAFEcoin +28.49%
#5 Saakuru Saakuru +24.27%
#6 StakeStone StakeStone +19.47%
#7 Yooldo Games Yooldo Games +16.45%
#8 Particle Network Particle Network +16.23%
#9 TronBank TronBank +13.65%
#10 Arcblock Arcblock +13.56%
Coin of the day
NKN NKN
설정
언어
한국어
통화
USD
테마
Intellipharmaceutics International Inc. Intellipharmaceutics International Inc.

Intellipharmaceutics International Inc.

IPCIF
주식 순위 #99999
Intellipharmaceutics International Inc., a pharmaceutical company, researches,... Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. It also provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. In addition, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.
주가
$0.15
시가총액
$4.96M
변동 (1일)
0.00%
변동 (1년)
0.00%
국가
CA
거래 Intellipharmaceutics International Inc. (IPCIF)

카테고리

Healthcare
Intellipharmaceutics International Inc. (IPCIF)의 배당 이력
Intellipharmaceutics International Inc. (주식 심볼: IPCIF)은 총 0회의 배당금을 지급했습니다.
모든 배당금의 합계 (주식 분할 반영): 0.00
배당 수익률 (TTM): 0
Intellipharmaceutics International Inc. (IPCIF)의 2026부터 2026까지 배당 지급 내역
연간 배당 지급
연도 배당금 (주식 분할 조정됨) 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
모든 배당 지급 목록
연도 배당금 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 배당 지급
회사 배당 지급 횟수 국가
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
52.00%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
5.00%
US
UCB SA UCB SA
UCB SA
UCB.BR
29.00%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL